Aposense

  • Home
  • About Us
    • Our mission and vision
    • Scientific president
    • Team
    • Board of directors
    • Scientific advisory board
    • Intellectual property
  • Our Technology
  • Our Platform
  • Investors
    • Presentations
    • Financial Reports
    • Stock Information
  • News Room
    • Press release
    • Publications
  • Other Projects
    • ATT-11T: Anti cancer pro-drug
    • ML-10
  • Contact Us


Aposense has signed a definitive agreement with SirVir Ltd. A private company, jointly owned by Aposense, Prof. Roger D. Kornberg, and Access Industries Holdings LLC. SirVir will engage in the development and commercialization of products in the field of treatment of respiratory viral infections, based on the Apo-Si technology developed by the Company

01/08/2019

Click Here

press release
Aposense

Contact Us

Telephone: + 972.73.239.7600
Fax: +972.3.921.57.14
E-mail: info@aposense.com

Careers

Latest news

  • Aposense has signed a definitive agreement with SirVir Ltd. A private company, jointly owned by Aposense, Prof. Roger D. Kornberg, and Access Industries Holdings LLC. SirVir will engage in the development and commercialization of products in the field of treatment of respiratory viral infections, based on the Apo-Si technology developed by the Company

    8 Jan 2019

  • Notice: Convening of a Shareholders Meeting

    17 Sep 2018

  • The Company is pleased to announce the signing of a non-binding Term Sheet with Prof. Roger D. Kornberg, who was awarded the Nobel Prize in Chemistry in 2006 and is the Scientific President of the Company and Access Industries Inc for the formation of a joint venture. The joint venture will engage in the development and commercialization of products in the field of treatment of respiratory viral infections, based on the Apo-Si technology developed by the Company

    15 Aug 2018

Aposense © 2019. Privacy Policy
  • Home
  • About Us
    ▼
    • Our mission and vision
    • Scientific president
    • Team
    • Board of directors
    • Scientific advisory board
    • Intellectual property
  • Our Technology
  • Our Platform
  • Investors
    ▼
    • Presentations
    • Financial Reports
    • Stock Information
  • News Room
    ▼
    • Press release
    • Publications
  • Other Projects
    ▼
    • ATT-11T: Anti cancer pro-drug
    • ML-10
  • Contact Us